Opthea has announced new data from a Phase 2b clinical trial using sozinibercept to treat neovascular age-related macular degeneration (nAMD).

Pensioners needing treatment for neovascular age-related macular degeneration (nAMD) pay up to 20% of their income on treatment and management of the disease, according

Two new studies, published last month, have shed further light on the effect of repeated low-level red-light (RLRL) therapy.

Ever wondered about the outcomes that can be achieved with early and proactive intervention to manage glaucoma?